Who Paid My Doc
Dean Kereiakes
Interventional Cardiology Cincinnati, OH Medical Doctor
NPI 1427025055 CMS profile 64866
2123 Auburn Ave Ste 136, Cincinnati, OH 45219
General payments
$138,721
Research payments
$3,049
Ownership & investment interest
$5,574
Research they led as principal investigator
$3,270,967
Through program year 2025, Dean Kereiakes of Cincinnati, OH is reported in the CMS Open Payments database as having received $138,721 across 204 general payments and $3,049 in research payments paid to them. Separately, studies naming them as principal investigator received $3,270,967 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $5,574 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,854 | 37 | |
| 2024 | General | $13,936 | 21 | |
| 2023 | General | $16,422 | 30 | |
| 2022 | General | $26,149 | 30 | |
| 2022 | Research | $50 | 1 | |
| 2021 | General | $23,182 | 15 | |
| 2020 | General | $32,660 | 16 | |
| 2019 | General | $17,518 | 55 | |
| 2019 | Research | $2,999 | 1 | |
| 2023 | Ownership | $3,374 | 1 | |
| 2021 | Ownership | $2,200 | 1 |
Beside peers
- Dean Kereiakes
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Dean Kereiakes were reported at $8,854. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Dean Kereiakes | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $17,518 | $1,097 | $329–$3,048 | $163 |
| 2020 | $32,660 | $473 | $161–$1,480 | $114 |
| 2021 | $23,182 | $677 | $233–$1,827 | $132 |
| 2022 | $26,149 | $978 | $333–$2,724 | $149 |
| 2023 | $16,422 | $1,136 | $382–$2,986 | $160 |
| 2024 | $13,936 | $1,181 | $395–$3,326 | $164 |
| 2025 | $8,854 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
531
Drug cost
$85,189
Branded share of claims
35%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Repatha Sureclick Evolocumab | Brand | 39 | $26,663 | |
| Praluent Pen Alirocumab | Brand | 16 | $18,604 | |
| Entresto Sacubitril/Valsartan | Brand | 22 | $16,066 | |
| Eliquis Apixaban | Brand | 18 | $13,740 | |
| Ezetimibe | Generic | 53 | $2,460 | |
| Eplerenone | Generic | 23 | $1,470 | |
| Amlodipine-Olmesartan Amlodipine Bes/Olmesartan Med | Brand | 23 | $1,222 | |
| Rosuvastatin Calcium | Generic | 51 | $926 | |
| Bisoprolol Fumarate | Generic | 28 | $792 | |
| Olmesartan-Amlodipine-Hctz Olmesartan/Amlodipin/Hcthiazid | Brand | 12 | $640 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$30,635
Medicare patients
338
Services billed
436
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Arthritis | 49% | |
| Diabetes | 30% | |
| Atrial fibrillation | 30% | |
| Chronic kidney disease | 27% | |
| Heart failure | 22% | |
| Cancer | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
206 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Ohio
Gary Ansel
Interventional Cardiology · Columbus, OH
John Cheatham
Interventional Cardiology · Columbus, OH
Carlos Sanchez Soto
Interventional Cardiology · Columbus, OH
Steven Yakubov
Interventional Cardiology · Columbus, OH
Timothy Henry
Interventional Cardiology · Cincinnati, OH
Mitchell Silver
Interventional Cardiology · Columbus, OH
Related records
Interventional Cardiology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.